1/8/2024 0 Comments Wolf piezowave 2![]() ![]() The study was conducted in accordance with the principles of the Helsinki Declaration, and approved by the Ministry of Health of the Czech Republic and by the 1st Faculty of Medicine, Charles University. The present study aims to assess the safety and efficacy of a shockwave device, the Piezowave² device of Richard Wolf GmbH, which offers substantially superior treatment parameters and organ coverage using a new Linear Shockwave Tissue Coverage LSTC-ED ® technique. Current methods for treating vasculogenic ED aim to reduce symptoms rather than reverse the cause of the disorder, which in most cases is due to disorders affecting arterial inflow, so the use of shockwaves to treat ED has been evaluated using a modified orthopedic device. ![]() It has been demonstrated that shockwaves can improve intrinsic angiogenic activity when used to treat ischemic heart disease. Vascular diseases such as diabetes mellitus or atherosclerotic vascular occlusive disease are present in up to 60% of ED patients. Alterations in the vascular hemodynamics are believed to be the most common cause of organic erectile dysfunction. The association between vascular disease and erectile dysfunction has been recognized and well documented. Piezowave 2, LSTC-ED ®, Erectile Dysfunction, Extracorporeal Shockwaves, Low Intensity Shockwave TherapyĮrectile dysfunction (ED) is defined as inability to achieve or maintain erection adequate for sexual intercourse. The Piezowave 2 device and the LSTC-ED ® technique proved to be suitable and effective to treat erectile dysfunction. No significant adverse effects were observed during treatment or in the follow-up period. In the placebo group of 50 patients only 5 patients showed an improvement based on IIEF score, and 8 reported an improvement based on their answers to the TSQ. According to the Treatment Satisfaction Questionnaire (answers 1 to 3 of the TSQ), treatment was successful in 77.3% of patients (58/75). According to the IIEF-5 scale, treatment was successful in 81.33% of patients (61/75). The average IIEF-5 score of patients in the treatment group increased from 14.4 at baseline to 18.6 at 1 month post treatment. The study also included a group of 50 patients treated by placebo the outcomes of both groups were compared. Patients’ erectile function was evaluated using the modified IIEF-5 (International Index of Erectile Function) scale at the beginning of treatment and at 1 month post treatment patients were additionally questioned using our own Treatment Satisfaction Questionnaire (TSQ). A total of 75 patients were treated using the Piezowave 2 device and the LSTC-ED ® technique. The present study aimed to demonstrate the efficacy of a linear focused piezoelectric shockwave device (Richard Wolf/ELvationPiezowave 2) to treat patients with vasculogenic ED using a novel linear shockwave tissue coverage LSTC-ED ® technique. ![]() The method has been evaluated and is used to treat vasculogenic erectile dysfunction (ED). Low intensity shockwave (LiSW) treatment is known to improve revascularization. Received 20 February 2016 accepted 4 April 2016 published 7 April 2016 This work is licensed under the Creative Commons Attribution International License (CC BY). 1Urology and Andrology Center, Brno, Czech RepublicĢUrology and Andrology Center, Banska Bystrica, SlovakiaģDepartment of Urology and Institute of Sexology, The 1st Facullty of Medicine, Charles University, Prague, Czech RepublicĬopyright © 2016 by authors and Scientific Research Publishing Inc. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |